Mark Foley
Dieser Inhalt ist noch nicht in deiner Sprache verfügbar.
Mark Foley is a former Chief Executive Officer of Revance Therapeutics. In the Botulinum Index graph, he is useful as a historical leadership node for the period when Revance brought Daxxify into the U.S. botulinum toxin market.
His page should be read through the product-development and commercialization record, not as a current Revance leadership profile. Current Revance leadership sits within the Revance / Crown Laboratories company context after Crown’s 2025 acquisition.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Historical organization | Revance Therapeutics |
| Relevant historical role | Chief Executive Officer |
| Current graph role | Historical executive node for Daxxify approval and early commercialization |
| Relevant company node | Revance / Crown Laboratories |
| Relevant brand node | Daxxify |
| Product approval anchor | FDA original approval date for Daxxify: September 7, 2022 |
Career Notes
Section titled “Career Notes”- Foley was publicly identified as Revance Therapeutics’ Chief Executive Officer during the company’s public-company period.
- Daxxify received its original U.S. approval for temporary improvement of moderate to severe glabellar lines on September 7, 2022.
- Revance later added a therapeutic U.S. label anchor for Daxxify in adult cervical dystonia.
- Crown Laboratories completed its acquisition of Revance in February 2025, moving the Revance business into a private-company context.
DAXXIFY Approval and Commercialization Context
Section titled “DAXXIFY Approval and Commercialization Context”Foley’s relevance comes from timing. Daxxify’s entry added a newer U.S. type A toxin product to the comparison field that already included Botox, Dysport, Xeomin, Jeuveau, and later Letybo. Revance described Daxxify as peptide-formulated, but that product distinction should not be converted into broad claims of unit equivalence, clinical superiority, or universal duration advantage.
The safer graph interpretation is narrower: Foley anchors the Revance executive period around Daxxify’s approval and early market development, while Daxxify’s indications, units, and safety language remain governed by its product-specific label.
Activity and Public Context
Section titled “Activity and Public Context”Foley is not the current leadership node for Revance after the Crown acquisition. That distinction prevents the site from mixing Revance Therapeutics’ public-company history with the post-acquisition Revance / Crown structure.
For current company context, readers should move from Foley to Revance / Crown Laboratories. For product interpretation, they should move from Foley to Daxxify and the FDA label record.